SEC Probes Aveo Over Failed Renal Cancer Drug
Aveo Pharmaceuticals Inc. on Thursday said the U.S. Securities and Exchange Commission has launched a probe in connection with the drugmaker's experimental kidney cancer drug, which in June was rejected by...To view the full article, register now.
Already a subscriber? Click here to view full article